Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25950253 | 0.88 | KDM4E (0.47) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL454478 | 0.86 | ALDH1A1 (0.35) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13430817 | 0.84 | HDAC3 (0.36) | — | |
| SCHEMBL12608885 | 0.84 | ADRB2 (0.36) | — | |
| SCHEMBL19728773 | 0.81 | HDAC3 (0.32) | — | |
| SCHEMBL12438076 | 0.81 | KDM4E (0.36) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21566545 | 0.76 | MEN1 (0.36) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL25952675 | 0.76 | TSHR (0.40) | — | |
| SCHEMBL25679031 | 0.75 | HDAC3 (0.33) | — | |
| SCHEMBL24054601 | 0.74 | LMNA (0.38) | KDM4ECYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | ELLIPSES PHARMA LTD (GB) | 2023-09-14 | — | — | US | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20210317235-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | NOVARTIS AG (CH) | 2021-10-14 | — | — | US | disclosed |
| US-20210154308-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20200375978-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | COLE RODERIC O (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20170362346-A1 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES | CERULEAN PHARMA INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110282047-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245201-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| US-20110160159-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110152512-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. | 2011-06-23 | — | — | US | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | KDM4E 4601/4885CYP1A2 3222/4885CYP2D6 2121/4885 |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | KDM4E 1873/4885CYP1A2 4130/4885CYP2D6 4510/4885 |
| US-20210154308-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | KDM4E 3228/4885CYP1A2 2986/4885CYP2D6 945/4885 |
| US-20230285576-A1 | TREATMENT OF CANCER USING A CYCLODEXTRIN-CONTAINING POLYMER-TOPOISOMERASE INHIBITOR CONJUGATE AND A PARP INHIBITOR | PARP1, TOP1, PARP2 | KDM4E 1012/4885CYP1A2 1211/4885CYP2D6 1392/4885 |
| US-20200375978-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | KDM4E 2821/4885CYP1A2 2158/4885CYP2D6 3224/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | KDM4E 4601/4885CYP1A2 3222/4885CYP2D6 2121/4885 |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | KDM4E 3228/4885CYP1A2 2986/4885CYP2D6 945/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | KDM4E 2688/4885CYP1A2 4585/4885CYP2D6 3781/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | KDM4E 3474/4885CYP1A2 4517/4885CYP2D6 3485/4885 |
| US-20110160159-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | KDM4E 2821/4885CYP1A2 2158/4885CYP2D6 3224/4885 |
| US-20180117168-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | JAK2, JAK3, JAK1 | KDM4E 2677/4885CYP1A2 4267/4885CYP2D6 3277/4885 |
| US-20110245201-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | KDM4E 2821/4885CYP1A2 2158/4885CYP2D6 3224/4885 |
| US-20180015170-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | KDM4E 4601/4885CYP1A2 3222/4885CYP2D6 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.